{
    "clinical_study": {
        "@rank": "16897", 
        "brief_summary": {
            "textblock": "The purpose of this study is to gain initial information on the tolerability of high-dose\n      capsaicin patches in patients with Painful Postherpetic Neuralgia. The study will also\n      collect preliminary information on safety and efficacy."
        }, 
        "brief_title": "Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain", 
        "completion_date": "October 2002", 
        "condition": [
            "Neuralgia", 
            "Pain", 
            "Peripheral Nervous System Diseases", 
            "Herpes Zoster"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Herpes Zoster", 
                "Nervous System Diseases", 
                "Neuralgia", 
                "Peripheral Nervous System Diseases", 
                "Neuralgia, Postherpetic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility Criteria\n\n        Inclusion Criteria:\n\n        Patients may be eligible for this study if they:\n\n          -  Have a diagnosis of Painful Postherpetic Neuralgia and are at least 6 months post\n             vesicle crusting.\n\n          -  Are in good health.\n\n          -  Have an adequate pain score during the screening period.\n\n          -  Have painful areas (maximum of two sites) below the neck.\n\n          -  If female, are of non-childbearing ability as defined by absence of menses for a\n             minimum of 3 months or surgically sterile.\n\n          -  If male, are willing to agree to take adequate birth control precautions with their\n             partner for 60 days following experimental drug exposure.\n\n          -  Have unbroken skin with good perfusion over the painful area(s).\n\n          -  Have the ability to feel capsaicin-mediated sensations, as evidenced by ability to\n             feel topically applied OTC capsaicin cream.\n\n          -  Are on a stable and continuous medication regimen, with no change in dosage for 21\n             days prior to study start, and are willing to maintain concomitant medications at\n             current doses throughout the study.\n\n          -  Are willing and able to use oral opioid-based analgesic agents for relief, in case\n             this is needed to relieve acute pain associated with the application of capsaicin\n             patches.\n\n          -  Are 18 years of age or older.\n\n          -  Are willing and able to comply with the protocol\n\n        Exclusion Criteria:\n\n        Patients will not be eligible for this study if they:\n\n          -  Have diffusely distributed neuropathic pain (i.e., pain that is evident in more than\n             2 different sites).  Subjects must not have significant pain outside the areas to be\n             treated.\n\n          -  Have any implanted medical device (spinal cord stimulator, intrathecal pump or\n             peripheral nerve stimulator) for the treatment of neuropathic pain.\n\n          -  Currently (within the past 21 days) use topically applied non-steroidal\n             anti-inflammatory drugs, local anesthetics, steroids or capsaicin products on the\n             painful areas.\n\n          -  Currently (within the past 21 days) use topical agents such as lidoderm patch 5%,\n             topical steroids or aspirin.\n\n          -  Have a history or current problem with prescription drug or illicit substance abuse\n             (from self report or as judged by investigator).\n\n          -  Currently have an abuse problem with alcohol (from self-report or as judged by\n             investigator).\n\n          -  Are suspected of psychosocial gain/benefit of continued pain as judged by the\n             investigator or primary treating physician.\n\n          -  Plan to travel more than 100 miles from home during the study or engage in unusual\n             activities that might exacerbate pain.\n\n          -  Have poor cardiac, renal, hepatic, or pulmonary function judged by the investigator\n             or primary treating physician.\n\n          -  Have a laboratory value at screening outside the normal range, unless it is judged by\n             the investigator as not clinically significant after appropriate evaluation.\n\n          -  Have hypersensitivity to capsaicin (i.e., chili peppers or OTC capsaicin products),\n             local anesthetics, oral opioid-based analgesic agents, or adhesives.\n\n          -  Have a high tolerance to opioids.\n\n          -  Currently using Class 1 anti-arrhythmic drugs (such as tocainide and mexiletine)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "42", 
        "firstreceived_date": "May 1, 2002", 
        "id_info": {
            "nct_id": "NCT00034710", 
            "org_study_id": "C102"
        }, 
        "intervention": {
            "intervention_name": "Capsaicin Patch", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Capsaicin"
        }, 
        "keyword": [
            "Analgesics/*therapeutic use", 
            "Capsaicin/*administration & dosage/adverse effects", 
            "Herpes Zoster/*complications/drug therapy", 
            "Neuralgia/*drug therapy/etiology", 
            "Pain", 
            "Capsicum", 
            "Pepper", 
            "Dermal assessment", 
            "Pain measurement", 
            "Diary", 
            "PHN", 
            "Postherpetic Neuralgia", 
            "allodynia", 
            "hyperalgesia", 
            "shingles", 
            "varicella"
        ], 
        "lastchanged_date": "February 6, 2006", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85023"
                    }, 
                    "name": "Arizona Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "University of Arizona Health Sciences Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34102"
                    }, 
                    "name": "Anchor Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Beach Gardens", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33410"
                    }, 
                    "name": "Palm Beach Neurological Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33701"
                    }, 
                    "name": "Suncoast Neuroscience Associates, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital, Pain Trials Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84108"
                    }, 
                    "name": "University of Utah Pain Management Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Hospital, Neurology Department"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Controlled Pilot Study of High-Dose Capsaicin Patches in the Treatment of Pain Associated With Postherpetic Neuralgia", 
        "overall_official": {
            "affiliation": "NeurogesX", 
            "last_name": "John A Jermano", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034710"
        }, 
        "source": "NeurogesX", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NeurogesX", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2006"
    }, 
    "geocoordinates": {
        "Anchor Research Center": "26.142 -81.795", 
        "Arizona Research Center": "33.448 -112.074", 
        "Brigham and Women's Hospital, Pain Trials Center": "42.358 -71.06", 
        "Palm Beach Neurological Center": "26.823 -80.139", 
        "Suncoast Neuroscience Associates, Inc.": "27.773 -82.64", 
        "University of Arizona Health Sciences Center": "32.222 -110.926", 
        "University of Utah Pain Management Center": "40.761 -111.891", 
        "University of Wisconsin Hospital, Neurology Department": "43.073 -89.401"
    }
}